HomeCompareSWMAF vs ABBV

SWMAF vs ABBV: Dividend Comparison 2026

SWMAF yields 100.50% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SWMAF wins by $3.87M in total portfolio value
10 years
SWMAF
SWMAF
● Live price
100.50%
Share price
$10.05
Annual div
$10.10
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.98M
Annual income
$1,344,310.50
Full SWMAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SWMAF vs ABBV

📍 SWMAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSWMAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SWMAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SWMAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SWMAF
Annual income on $10K today (after 15% tax)
$8,542.29/yr
After 10yr DRIP, annual income (after tax)
$1,142,663.93/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SWMAF beats the other by $1,121,607.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SWMAF + ABBV for your $10,000?

SWMAF: 50%ABBV: 50%
100% ABBV50/50100% SWMAF
Portfolio after 10yr
$2.04M
Annual income
$684,541.13/yr
Blended yield
33.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SWMAF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SWMAF buys
0
ABBV buys
0
No recent congressional trades found for SWMAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSWMAFABBV
Forward yield100.50%3.06%
Annual dividend / share$10.10$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$3.98M$102.3K
Annual income after 10y$1,344,310.50$24,771.77
Total dividends collected$3.55M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SWMAF vs ABBV ($10,000, DRIP)

YearSWMAF PortfolioSWMAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$20,750$10,049.75$11,550$430.00+$9.2KSWMAF
2$41,691$19,488.77$13,472$627.96+$28.2KSWMAF
3$81,205$36,595.70$15,906$926.08+$65.3KSWMAF
4$153,507$66,617.32$19,071$1,382.55+$134.4KSWMAF
5$281,944$117,692.20$23,302$2,095.81+$258.6KSWMAF
6$503,703$202,022.59$29,150$3,237.93+$474.6KSWMAF
7$876,271$337,308.51$37,536$5,121.41+$838.7KSWMAF
8$1,486,022$548,412.37$50,079$8,338.38+$1.44MSWMAF
9$2,459,225$869,181.33$69,753$14,065.80+$2.39MSWMAF
10$3,975,681$1,344,310.50$102,337$24,771.77+$3.87MSWMAF

SWMAF vs ABBV: Complete Analysis 2026

SWMAFStock

Swedish Match AB (publ) develops, manufactures, markets, and sells snus and moist snuff, lights, and other tobacco products in Scandinavia, the United States, and internationally. The company operates through Smokefree, Cigars, and Lights segments. It provides snus and pouch products, nicotine pouches, nicotine free products, and moist snuff under the General, Göteborgs Rapé, Kaliber, Kronan, Ettan, Grov, Catch, G.3, The Lab, Nick & Johnny, Thunder, VOLT, Swave, ZYN, G.4, Onico, Qvitt, Longhorn, and Timber Wolf brand names. The company offers chewing tobacco products under the Red Man and Big Duke brand names; chew bags under the Thunder and Göteborgs Rapé brands; and tobacco bits under the Oliver Twist brand name. In addition, it provides cigars under the Garcia y Vega, Game by Garcia y Vega, 1882, White Owl, and Jackpot brands; matches under the Solstickan, Nitedals, Fiat Lux, and Redheads brand names; lighters under the Cricket brand; and complementary products, such as razors, batteries, and light bulbs under the Fiat Lux brand name. Further, the company distributes third party tobacco products. It markets its products through convenience stores, tobacconists, gasoline stations, supermarkets, bars, restaurants, airports, and ferries, as well as e-commerce and own stores. The company was founded in 1915 and is headquartered in Stockholm, Sweden.

Full SWMAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SWMAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SWMAF vs SCHDSWMAF vs JEPISWMAF vs OSWMAF vs KOSWMAF vs MAINSWMAF vs JNJSWMAF vs MRKSWMAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.